Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 2.51% is 794% above its 5-year average of -0.36%, near the high end of its 5-year range (-38.28%–6.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 44.76% below its 12-month average of 4.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 2.51%.
RETURN ON EQUITY (ROE)
2.51%
RETURN ON EQUITY (ROE) AVG TTM
4.54%
RETURN ON EQUITY (ROE) AVG 3Y
1.74%
RETURN ON EQUITY (ROE) AVG 5Y
-0.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-44.76%
CURRENT VS 3Y AVG
+44.06%
CURRENT VS 5Y AVG
+794.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
+106.14%
vs the sector median at left
GoodRx Holdings, Inc.
Market Cap
$1.15B
Return on Equity (ROE)
2.51%
TTM Avg
4.54%
3Y Avg
1.74%
5Y Avg
-0.36%
Market Cap
$1.15B
Return on Equity (ROE)
-17.40%
TTM Avg
-189.25%
3Y Avg
-172.42%
5Y Avg
-134.67%
Market Cap
$1.13B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
Market Cap
$1.13B
Return on Equity (ROE)
10.23%
TTM Avg
17.11%
3Y Avg
18.25%
5Y Avg
14.55%
Market Cap
$1.13B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.17B
Return on Equity (ROE)
-50.93%
TTM Avg
-117.72%
3Y Avg
-113.46%
5Y Avg
-86.51%
Market Cap
$1.12B
Return on Equity (ROE)
-6.16%
TTM Avg
-10.85%
3Y Avg
-14.08%
5Y Avg
-9.38%
Market Cap
$1.11B
Return on Equity (ROE)
1.05%
TTM Avg
-23.37%
3Y Avg
-7.64%
5Y Avg
-0.10%
Market Cap
$1.10B
Return on Equity (ROE)
-281.14%
TTM Avg
-124.20%
3Y Avg
-84.35%
5Y Avg
-63.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GoodRx Holdings, Inc. (GDRX) | $1.15B | 2.51% | 4.54% | 1.74% | -0.36% |
| Nektar Therapeutics (NKTR)vs › | $1.15B | -17.40% | -189.25% | -172.42% | -134.67% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | 35.70% | 35.70% | 35.70% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 10.23% | 17.11% | 18.25% | 14.55% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -244.91% | -17.45% | -30.16% | -48.76% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | -50.93% | -117.72% | -113.46% | -86.51% |
| OPKO Health, Inc. (OPK)vs › | $1.12B | -6.16% | -10.85% | -14.08% | -9.38% |
| STAAR Surgical Company (STAA)vs › | $1.11B | 1.05% | -23.37% | -7.64% | -0.10% |
| Replimune Group, Inc. (REPL)vs › | $1.10B | -281.14% | -124.20% | -84.35% | -63.72% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -39.54% | -24.09% | 36.77% | 36.77% |
ROE
2.5%
ROA
0.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 2.51% |
| 2026-03-31 | 3.30% |
| 2025-12-31 | 4.94% |
| 2025-09-30 | 5.29% |
| 2025-06-30 | 6.67% |
| 2025-03-31 | 5.62% |
| 2024-12-31 | 3.41% |
| 2024-09-30 | -1.14% |
| 2024-06-30 | -8.77% |
| 2024-03-31 | -1.04% |
| 2023-12-31 | -1.16% |
| 2023-09-30 | 1.71% |
| 2023-06-30 | 1.32% |
| 2023-03-31 | -5.85% |
| 2022-12-31 | -4.03% |
| 2022-09-30 | -8.98% |
| 2022-06-30 | -5.76% |
| 2022-03-31 | -1.86% |
| 2021-12-31 | -3.04% |
| 2021-09-30 | -33.51% |
| 2021-06-30 | -38.28% |
| 2021-03-31 | -42.63% |
| 2020-12-31 | -41.28% |
| 2020-09-30 | 2.63% |
